The U.S. Supreme Court is reviewing Monsanto Company v. Durnell, a Roundup failure-to-warn case arising from a Missouri plaintiff’s verdict. A jury found for John Durnell on his strict liability failure-to-warn claim and awarded $1.25 million in compensatory damages. The Missouri Court of Appeals affirmed the judgment, and the Missouri Supreme Court declined further review before Monsanto sought review in the U.S. Supreme Court.
The issue before the Court is whether the Federal Insecticide, Fungicide, and Rodenticide Act, known as FIFRA, preempts a state-law warning claim where EPA has not required that warning. Monsanto argues that Durnell’s claim would impose a labeling requirement beyond federal law. Durnell’s response is that Missouri failure-to-warn law can operate alongside FIFRA because it parallels federal misbranding requirements rather than adding a different labeling rule. For Roundup claimants, the decision could affect whether failure-to-warn claims continue moving through state-law product liability channels or face broader preemption challenges.
The Supreme Court review is unfolding while other Roundup proceedings continue to move through the courts. In February 2026, Bayer announced a proposed $7.25 billion nationwide class settlement designed to address current and potential future Roundup claims. A Missouri state court later granted preliminary approval, but the settlement still faces additional hurdles, including opt-outs, objections, and final approval. In that settlement proceeding, objectors recently sought to move the case to federal court in the Eastern District of Missouri, where they argued the settlement should be reviewed in connection with the federal Roundup MDL.
As of this writing, the settlement-related removal dispute appears to remain unresolved, including whether the matter may be transferred to the federal Roundup MDL. Because these developments may affect how Roundup claims are litigated and resolved, Philadelphia mass tort lawyer Matt Leckman of Leckman Law is monitoring Roundup litigation closely. If you or a family member developed non-Hodgkin’s lymphoma after Roundup exposure, contact the firm to discuss whether the facts of your situation may support a potential claim.
Disclaimer: The articles on this blog are for informative purposes only and are no substitute for legal advice or an attorney-client relationship. Prior results and pending litigation developments do not guarantee any particular outcome, and claim eligibility may depend on the facts, applicable deadlines, jurisdiction, court rulings, and other legal considerations. If you are seeking legal advice, please contact Leckman Law directly.